Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PA83-FhCMB
- Development stage
- Phase 1
- Lead developer
- iBio
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
PA83-FhCMB is a plant-derived recombinant protective antigen anthrax vaccine designed to protect against anthrax by inducing an immune response. It is formulated with Alhydrogel adjuvant and targets the protective antigen (PA) of Bacillus anthracis, a key component of the lethal and edema toxins. The vaccine has shown safety and immunogenicity in Phase 1 clinical trials.
- Brand names
- PA83-FhCMB + Alhydrogel
- Other names
- Plant-derived recombinant protective antigen anthrax vaccine
02
Targets
PA (Influenza polymerase acidic protein)
Beyond the preview
Go deeper on PA83-FhCMB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PA83-FhCMB.